A well-executed regulatory strategy is essential for successful drug and biologics development and approval. Regulatory professionals, such as Global Regulatory Leads (GRL), navigate complex processes governed by the US Code of Federal Regulations (CFR) and relevant regulatory standards. Critical steps in this strategy include investigational new drug (IND) applications, biologics license applications (BLA), and new drug applications (NDA), where adherence to the U.S. Food and Drug Administration’s (US-FDA) guidelines, such as Good Clinical Practice (GCP) and Current Good Manufacturing Practice (cGMP), is paramount. The FDA utilizes Prescription Drug User Fee Act (PDUFA) dates to streamline review timelines and hosts multiple meeting types (Type A, B, and C) for direct dialogue, often to resolve issues preemptively or ensure continuous development support. Key stages also involve the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), both pivotal in determining safety and efficacy standards. Regulatory flexibility and thorough preparation for Advisory Committee (AdCom) meetings, FDA audits, and inspections mitigate risks of Form-483 observations or Warning Letters. Effective strategies must prioritize chemistry, manufacturing, and controls (CMC) compliance and address Institutional Review Board (IRB) requirements, with clear action plans for managing all communication channels.